Matches in SemOpenAlex for { <https://semopenalex.org/work/W2108687521> ?p ?o ?g. }
Showing items 1 to 89 of
89
with 100 items per page.
- W2108687521 endingPage "1494" @default.
- W2108687521 startingPage "1488" @default.
- W2108687521 abstract "OBJECTIVE: To review the chemistry, pharmacology, pharmacokinetics, clinical efficacy, and safety of atovaquone. DATA IDENTIFICATION: An English-language literature search using MEDLINE (1984-1993), programs and abstracts of the 30th, 31st, and 32nd Interscience Conferences on Antimicrobial Agents and Chemotherapy, program and abstracts of the VIII International Conference on AIDS, and unpublished information from Burroughs Wellcome, the manufacturer of atovaquone. STUDY SELECTION: All available pharmacokinetic and clinical trials were reviewed. DATA EXTRACTION: Study quality was assessed by a critical appraisal of study design and methods. Pharmacokinetic studies were evaluated for sampling, methods used to determine pharmacokinetic properties, and the presence of concentration-response and concentration-toxicity relationships. Clinical trials were assessed primarily for comparative efficacy and toxicity. RESULTS: Atovaquone is a novel hydroxynaphthoquinone with potent activity against Pneumocystis carinii and Toxoplasma gondii. Its pharmacokinetic properties are characterized by relatively poor bioavailability, excretion almost exclusively through the feces, lack of hepatic metabolism and urinary excretion, low steady-state plasma concentrations, high protein binding, and a long elimination half-life (50-70 h). Results from comparative clinical trials in AIDS patients with mild-to-moderate P. carinii pneumonia (PCP) reveal similar overall treatment success rates for atovaquone, trimethoprim/sulfamethoxazole (TMP/SMX), and pentamidine. Treatment failure because of lack of therapeutic response was significantly greater in patients who received atovaquone compared with those treated with TMP/SMX (p=0.002). More atovaquone-patients experienced treatment failure compared with their pentamidine-treated counterparts, although statistical significance was not achieved. Treatment failure secondary to drug toxicity was significantly higher in the TMP/SMX- and pentamidine-treated patients (p<0.01). Atovaquone has not been studied for PCP prophylaxis. Limited data exist on the use of atovaquone for toxoplasmic encephalitis (TE); however, results from an open trial reveal that the drug may be useful in treating this disorder. To date, atovaquone has been well tolerated by most patients administered the drug. The most common adverse effects include maculopapular rash, gastrointestinal disturbances, and fever. Atovaquone is considerably more costly than other oral agents used to treat PCP. CONCLUSIONS: Atovaquone appears to be better tolerated but less effective than TMP/SMX and pentamidine in the treatment of mild-to-moderate PCP. There is not enough information available on the use of atovaquone for PCP prophylaxis or the treatment of TE to definitively describe its efficacy. Comparative clinical trials are needed to assess its role in this clinical setting." @default.
- W2108687521 created "2016-06-24" @default.
- W2108687521 creator A5050079986 @default.
- W2108687521 creator A5079900298 @default.
- W2108687521 date "1993-12-01" @default.
- W2108687521 modified "2023-10-03" @default.
- W2108687521 title "ATOVAQUONE: A Review" @default.
- W2108687521 cites W1965527205 @default.
- W2108687521 cites W1975354132 @default.
- W2108687521 cites W1981742733 @default.
- W2108687521 cites W1987070293 @default.
- W2108687521 cites W1988190564 @default.
- W2108687521 cites W2007561244 @default.
- W2108687521 cites W2025781604 @default.
- W2108687521 cites W2040327363 @default.
- W2108687521 cites W2052977448 @default.
- W2108687521 cites W2089071734 @default.
- W2108687521 cites W2118833767 @default.
- W2108687521 cites W2342351290 @default.
- W2108687521 doi "https://doi.org/10.1177/106002809302701215" @default.
- W2108687521 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8305784" @default.
- W2108687521 hasPublicationYear "1993" @default.
- W2108687521 type Work @default.
- W2108687521 sameAs 2108687521 @default.
- W2108687521 citedByCount "58" @default.
- W2108687521 countsByYear W21086875212012 @default.
- W2108687521 countsByYear W21086875212013 @default.
- W2108687521 countsByYear W21086875212014 @default.
- W2108687521 countsByYear W21086875212015 @default.
- W2108687521 countsByYear W21086875212017 @default.
- W2108687521 countsByYear W21086875212018 @default.
- W2108687521 countsByYear W21086875212019 @default.
- W2108687521 countsByYear W21086875212020 @default.
- W2108687521 countsByYear W21086875212021 @default.
- W2108687521 countsByYear W21086875212022 @default.
- W2108687521 countsByYear W21086875212023 @default.
- W2108687521 crossrefType "journal-article" @default.
- W2108687521 hasAuthorship W2108687521A5050079986 @default.
- W2108687521 hasAuthorship W2108687521A5079900298 @default.
- W2108687521 hasConcept C112705442 @default.
- W2108687521 hasConcept C126322002 @default.
- W2108687521 hasConcept C203014093 @default.
- W2108687521 hasConcept C2778048844 @default.
- W2108687521 hasConcept C2778371730 @default.
- W2108687521 hasConcept C2779124865 @default.
- W2108687521 hasConcept C2780728791 @default.
- W2108687521 hasConcept C29730261 @default.
- W2108687521 hasConcept C501593827 @default.
- W2108687521 hasConcept C535046627 @default.
- W2108687521 hasConcept C71924100 @default.
- W2108687521 hasConcept C86803240 @default.
- W2108687521 hasConcept C89423630 @default.
- W2108687521 hasConcept C98274493 @default.
- W2108687521 hasConceptScore W2108687521C112705442 @default.
- W2108687521 hasConceptScore W2108687521C126322002 @default.
- W2108687521 hasConceptScore W2108687521C203014093 @default.
- W2108687521 hasConceptScore W2108687521C2778048844 @default.
- W2108687521 hasConceptScore W2108687521C2778371730 @default.
- W2108687521 hasConceptScore W2108687521C2779124865 @default.
- W2108687521 hasConceptScore W2108687521C2780728791 @default.
- W2108687521 hasConceptScore W2108687521C29730261 @default.
- W2108687521 hasConceptScore W2108687521C501593827 @default.
- W2108687521 hasConceptScore W2108687521C535046627 @default.
- W2108687521 hasConceptScore W2108687521C71924100 @default.
- W2108687521 hasConceptScore W2108687521C86803240 @default.
- W2108687521 hasConceptScore W2108687521C89423630 @default.
- W2108687521 hasConceptScore W2108687521C98274493 @default.
- W2108687521 hasIssue "12" @default.
- W2108687521 hasLocation W21086875211 @default.
- W2108687521 hasLocation W21086875212 @default.
- W2108687521 hasOpenAccess W2108687521 @default.
- W2108687521 hasPrimaryLocation W21086875211 @default.
- W2108687521 hasRelatedWork W1982282930 @default.
- W2108687521 hasRelatedWork W2016793986 @default.
- W2108687521 hasRelatedWork W2064266978 @default.
- W2108687521 hasRelatedWork W2141289501 @default.
- W2108687521 hasRelatedWork W2418368050 @default.
- W2108687521 hasRelatedWork W2774225352 @default.
- W2108687521 hasRelatedWork W3008458259 @default.
- W2108687521 hasRelatedWork W4239075073 @default.
- W2108687521 hasRelatedWork W4245745103 @default.
- W2108687521 hasRelatedWork W4364376666 @default.
- W2108687521 hasVolume "27" @default.
- W2108687521 isParatext "false" @default.
- W2108687521 isRetracted "false" @default.
- W2108687521 magId "2108687521" @default.
- W2108687521 workType "article" @default.